RAL (6), theparent compound of this study, is known to exhibit cytotoxicity acrossvarious cell lines including HepG2 cells, most likely through an arylhydrocarbon receptor (AhR)-mediated process.55 Despite these cytotoxic side effects, RAL (6) possessesan acceptable benefit-risk profile that enabled its approval for long-termmedication against postmenopausal osteoporosis. The gene discussed is AHR; the disease is postmenopausal osteoporosis.